Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135489 | 1.00 | FAAH (0.57) | FAAHHTR1DGRIN2BCYP11B2L3MBTL3 | |
| SCHEMBL4141990 | 1.00 | FAAH (0.57) | FAAHHTR1DGRIN2BCYP11B2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL29113494 | 0.98 | FAAH (0.56) | FAAHHTR1DGRIN2BCYP11B2L3MBTL3 | |
| SCHEMBL2085025 | 0.98 | FAAH (0.56) | FAAHHTR1DGRIN2BCYP11B2L3MBTL3 | |
| SCHEMBL29113473 | 0.97 | FAAH (0.57) | FAAHHTR1DGRIN2BCYP11B2L3MBTL3 | |
| SCHEMBL24698220 | 0.90 | L3MBTL3 (0.48) | FAAHHTR1DGRIN2BL3MBTL3MBTD1 | |
| SCHEMBL24698754 | 0.90 | L3MBTL3 (0.48) | FAAHHTR1DGRIN2BL3MBTL3MBTD1 | |
| SCHEMBL2085878 | 0.86 | FAAH (0.54) | FAAHHTR1DGRIN2BCYP11B2ADRA2A | |
| Hydrochloric Acid SCHEMBL9341249 | 0.85 | FAAH (0.53) | FAAHHTR1DGRIN2BCYP11B2ADRA2A | |
| SCHEMBL24740684 | 0.82 | HTR1D (0.47) | FAAHHTR1DGRIN2BL3MBTL3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
| EP-2307375-B1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | PFIZER (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8552035-B2 | Phenanthrenone compounds, compositions and methods | PFIZER INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120157502-A1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8148409-B2 | Phenathrenone compounds, compositons and methods | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-7902191-B2 | Histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100069444-A1 | PHENATHRENONE COMPOUNDS, COMPOSITONS AND METHODS | PFIZER, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070155754-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1720861-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082893-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | FAAH 217/4885HTR1D 25/4885GRIN2B 86/4885 |
| US-20120157502-A1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | NR3C2, NR3C1, MC2R | FAAH 3260/4885HTR1D 611/4885GRIN2B 240/4885 |
| US-20070155754-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | FAAH 135/4885HTR1D 82/4885GRIN2B 548/4885 |
| US-20100069444-A1 | PHENATHRENONE COMPOUNDS, COMPOSITONS AND METHODS | NR3C2, NR3C1, MC2R | FAAH 1715/4885HTR1D 288/4885GRIN2B 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.